medigraphic.com
Organo Oficial de la Sociedad Mexicana de Urología

2020, Number 2

<< Back Next >>

Rev Mex Urol 2020; 80 (2)

Antimicrobial resistance and extended spectrum beta-lactamases in urinary tract infections: A serious problem in Northern Mexico

Robles-Torres JI, Ocaña-Munguía MA, Madero-Morales PA, Ruíz-Galindo E, Garza-González E, Gómez-Guerra LS

Language: English
References: 29
Page: 1-12
PDF size: 412.92 Kb.


ABSTRACT

Objective: To describe the causal agents, prevalence of antimicrobial resistance, and risk factors associated with extended spectrum beta-lactamase (ESBL)- producing agents in urinary tract infections (UTIs).
Materials and methods: A retrospective study was conducted at a tertiary care hospital in Monterrey, Mexico. Inclusion criteria were patients that clinically presented with a UTI and had a positive urine culture, within the time frame of March to October 2017. The association with ESBL-producing agents was determined through the χ2 test for categorical variables. Statistical significance was set at a p ‹0.05, utilizing SPSS version 20.0 software.
Results: A total of 353 positive urine cultures were confirmed. ESBL production was found in 21.5% of the strains. There was a high level of resistance (›50%) to amoxicillin-clavulanate, ciprofloxacin, levofloxacin, fosfomycin, and trimethoprim-sulfamethoxazole and moderate resistance (10-50%) to gentamicin and ceftriaxone. Amikacin, ertapenem, nitrofurantoin, and colistin had the lowest resistance rates (‹10%). The ESBL-producing agents were associated with complicated UTI (p≤0.0001). The comorbidities associated with ESBL-positive UTIs were diabetes mellitus (p=0.02) and immunodeficiency (p=0.008), as was having undergone radiotherapy (p=0.025) and previous antibiotic use (p≤0.001).
Limitations: The clonal relationship of isolates, especially of E. coli, was not analyzed. We could not establish whether there was a high level of genetic diversity between the isolates or whether independent acquisition or cross-transmission occurred.
Value: We evaluated the epidemiologic characteristics of the ESBL-producing agents in UTIs at a Mexican tertiary care hospital.
Conclusions: One out of every five UTIs was caused by ESBLs in our study population. There was a high level of resistance to the antibiotics used as first-line empiric therapy in the patients studied.


REFERENCES

  1. Foxman B. The epidemiology of urinary tract infection. Nature Reviews Urology. 2010 Dec;7(12):653–60. doi: https://doi. org/10.1038/nrurol.2010.190

  2. Litwin Mark S., Saigal Christopher S., Yano Elizabeth M., Avila Chantal, Geschwind Sandy A., Hanley Jan M., et al. Urologic diseases in america project: analytical methods and principal findings. Journal of Urology. 2005 Mar 1;173(3):933–7. doi: https://doi. org/10.1097/01.ju.0000152365.43125.3b

  3. Secretaría de Salud. Información Epidemiológica de Morbilidad. SUIVE/DGE/ Secretaría de Salud/Estados Unidos Mexicanos 2017. 2017. [accessed 25 Apr 2020] Available from: https://www.gob.mx/salud/acciones-yprogramas/ anuarios-de-morbilidad-1984-2018

  4. Grabe M, Bjerklund-Johansen TE, Botto H, Çek M, Naber KG, Tenke P, et al. Guidelines on urological infections. European association of urology. 2015;182.

  5. Naber KG, Schito G, Botto H, Palou J, Mazzei T. Surveillance study in Europe and Brazil on clinical aspects and Antimicrobial Resistance Epidemiology in Females with Cystitis (ARESC): implications for empiric therapy. Eur Urol. 2008 Nov;54(5):1164–75. doi: https://doi. org/10.1016/j.eururo.2008.05.010

  6. Nicolle LE. A Practical Guide to the Management of Complicated Urinary Tract Infection. Drugs. 1997 Apr 1;53(4):583–92. doi: https://doi. org/10.2165/00003495-199753040-00004

  7. Laupland KB, Ross T, Pitout JDD, Church DL, Gregson DB. Community-onset Urinary Tract Infections: A Population-based Assessment. Infection. 2007 Jun 1;35(3):150. doi: https:// doi.org/10.1007/s15010-007-6180-2

  8. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, et al. Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America. Clin Infect Dis. 2009 Jan 1;48(1):1–12. doi: https:// doi.org/10.1086/595011

  9. Zowawi HM, Harris PNA, Roberts MJ, Tambyah PA, Schembri MA, Pezzani MD, et al. The emerging threat of multidrug-resistant Gram-negative bacteria in urology. Nature Reviews Urology. 2015 Oct;12(10):570–84. doi: https://doi.org/10.1038/nrurol.2015.199

  10. Tal Jasper R, Coyle JR, Katz DE, Marchaim D. The complex epidemiology of extended-spectrum β-lactamase-producing Enterobacteriaceae. Future Microbiology. 2015 May 1;10(5):819– 39. doi: https://doi.org/10.2217/fmb.15.16

  11. Calbo E, Romaní V, Xercavins M, Gómez L, Vidal CG, Quintana S, et al. Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum β-lactamases. J Antimicrob Chemother. 2006 Apr 1;57(4):780–3. doi: 10.1093/jac/dkl035

  12. Rodríguez-Baño J, Navarro MD, Romero L, Muniain MA, Perea EJ, Pérez-Cano R, et al. Clinical and Molecular Epidemiology of Extended-Spectrum β -Lactamase—Producing Escherichia coli as a Cause of Nosocomial Infection or Colonization: Implications for Control. Clin Infect Dis. 2006 Jan 1;42(1):37– 45. doi: https://doi.org/10.1086/498519

  13. Briongos-Figuero LS, Gómez-Traveso T, Bachiller-Luque P, González MD-G, Gómez-Nieto A, Palacios-Martín T, et al. Epidemiology, risk factors and comorbidity for urinary tract infections caused by extendedspectrum beta-lactamase (ESBL)-producing enterobacteria. International Journal of Clinical Practice. 2012;66(9):891–6. doi: https://doi. org/10.1111/j.1742-1241.2012.02991.x

  14. Saltoglu N, Karali R, Yemisen M, Ozaras R, Balkan II, Mete B, et al. Comparison of community-onset healthcare-associated and hospital-acquired urinary infections caused by extended-spectrum beta-lactamaseproducing Escherichia coli and antimicrobial activities. International Journal of Clinical Practice. 2015;69(7):766–70. doi: https://doi. org/10.1111/ijcp.12608

  15. Clinical & Laboratory Standards Institute (CLSI). M100Ed30 | Performance Standards for Antimicrobial Susceptibility Testing, 30th Edition. Wayne, Pennsylvania, USA.; 2017. [accessed 25 Apr 2020] Available from: https:// clsi.org/standards/products/microbiology/ documents/m100/

  16. Blanco VM, Maya JJ, Correa A, Perenguez M, Muñoz JS, Motoa G, et al. [Prevalence and risk factors for extended-spectrum β-lactamase-producing Escherichia coli causing community-onset urinary tract infections in Colombia]. Enferm Infecc Microbiol Clin. 2016 Nov;34(9):559–65. doi: https://doi. org/10.1016/j.eimc.2015.11.017

  17. Medina-Polo J, Arrébola-Pajares A, Pérez- Cadavid S, Benítez-Sala R, Sopeña-Sutil R, Lara-Isla A, et al. Extended-Spectrum Beta-Lactamase-Producing Bacteria in a Urology Ward: Epidemiology, Risk Factors and Antimicrobial Susceptibility Patterns. UIN. 2015;95(3):288–92. doi: https://doi. org/10.1159/000439441

  18. Hernández-Vergara JA, Martínez-Santos VI, Radilla-Vázquez RB, Silva-Sánchez J, Vences-Velásquez A, Castro-Alarcón N. Characterization of Escherichia coli clinical isolates causing urinary tract infections in the community of Chilpancingo, Mexico. Int Microbiol. 2016 Dec;19(4):209–15. doi: https:// doi.org/10.2436/20.1501.01.279

  19. Cornejo-Dávila V, Palmeros-Rodríguez MA, Uberetagoyena-Tello de Meneses I, Mayorga- Gómez E, Garza-Sáinz G, Osornio-Sánchez V, et al. Management of complicated urinary tract infections in a referral center in Mexico. Int Urol Nephrol. 2015 Feb 1;47(2):229–33. doi: https:// doi.org/10.1007/s11255-014-0883-y

  20. Colodner R, Rock W, Chazan B, Keller N, Guy N, Sakran W, et al. Risk Factors for the Development of Extended-Spectrum Beta-Lactamase-Producing Bacteria in Nonhospitalized Patients. Eur J Clin Microbiol Infect Dis. 2004 Mar 1;23(3):163–7. doi: https://doi.org/10.1007/s10096-003-1084-2

  21. Ben-Ami R, Rodríguez-Baño J, Arslan H, Pitout JDD, Quentin C, Calbo ES, et al. A Multinational Survey of Risk Factors for Infection with Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae in Nonhospitalized Patients. Clin Infect Dis. 2009 Sep 1;49(5):682–90. doi: https://doi.org/10.1086/604713

  22. Alcántar-Curiel MD, Alpuche-Aranda CM, Varona-Bobadilla HJ, Gayosso-Vázquez C, Jarillo-Quijada MaD, Frías-Mendivil M, et al. Risk factors for extended-spectrum b-lactamases-producing Escherichia coli urinary tract infections in a tertiary hospital. Salud Publica Mex. 2015 Sep 12;57(5):412. doi: http://dx.doi.org/10.21149/spm.v57i5.7621

  23. Lee DS, Lee CB, Lee S-J. Prevalence and Risk Factors for Extended Spectrum Beta-Lactamase- Producing Uropathogens in Patients with Urinary Tract Infection. Korean Journal of Urology. 2010 Jul 1;51(7):492–7. doi: https:// doi.org/10.4111/kju.2010.51.7.492

  24. Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, et al. International Clinical Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women: A 2010 Update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011 Mar 1;52(5):e103–20. doi: https://doi.org/10.1093/cid/ciq257

  25. Vardakas KZ, Legakis NJ, Triarides N, Falagas ME. Susceptibility of contemporary isolates to fosfomycin: a systematic review of the literature. Int J Antimicrob Agents. 2016 Apr;47(4):269–85. doi: https://doi. org/10.1016/j.ijantimicag.2016.02.001

  26. Sorlozano A, Jimenez-Pacheco A, de Dios Luna Del Castillo J, Sampedro A, Martinez- Brocal A, Miranda-Casas C, et al. Evolution of the resistance to antibiotics of bacteria involved in urinary tract infections: a 7-year surveillance study. Am J Infect Control. 2014 Oct;42(10):1033–8. doi: https://doi. org/10.1016/j.ajic.2014.06.013

  27. Salles MJC, Zurita J, Mejía C, Villegas MV. Resistant Gram-negative infections in the outpatient setting in Latin America. Epidemiology & Infection. 2013 Dec;141(12):2459–72. doi: https://doi.org/10.1017/S095026881300191X

  28. Andrade SS, Sader HS, Jones RN, Pereira AS, Pignatari AC, Gales AC. Increased resistance to first-line agents among bacterial pathogens isolated from urinary tract infections in Latin America: time for local guidelines? Memórias do Instituto Oswaldo Cruz. 2006 Nov;101 (7):741–8. doi: https://doi.org/10.1590/S0074- 02762006000700006

  29. Brennan TA, Rothman DJ, Blank L, Blumenthal D, Chimonas SC, Cohen JJ, et al. Health Industry Practices That Create Conflicts of Interest: A Policy Proposal for Academic Medical Centers. JAMA. 2006 Jan 25;295(4):429–33. doi: https:// doi.org/10.1001/jama.295.4.429




2020     |     www.medigraphic.com